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1. INTRODUCTION {#dom13240-sec-0005}
===============

Obesity is a multifactorial condition of pandemic dimensions,[1](#dom13240-bib-0001){ref-type="ref"} which is often accompanied by perturbation of glucose and lipid homeostasis, together increasing the risk of developing type 2 diabetes mellitus, cardiovascular disease and fatty liver disease.[2](#dom13240-bib-0002){ref-type="ref"}, [3](#dom13240-bib-0003){ref-type="ref"} In addition to diet and other environmental factors, gut microbiota has been linked to the metabolic health status of an individual.[4](#dom13240-bib-0004){ref-type="ref"}, [5](#dom13240-bib-0005){ref-type="ref"} Concurrent with host physiology, the gut microbiota develops dynamically in the first years of life and is shaped by intrinsic and extrinsic factors, with nutrition playing a significant role.[6](#dom13240-bib-0006){ref-type="ref"} It is now commonly accepted that nutrition in early postnatal life has a pronounced impact on lifelong metabolic health,[7](#dom13240-bib-0007){ref-type="ref"}, [8](#dom13240-bib-0008){ref-type="ref"}, [9](#dom13240-bib-0009){ref-type="ref"} often referred to as nutritional programming. For instance, breastfed children have a higher abundance of bifidobacteria and a lower risk of developing obesity, glucose intolerance and hypercholesterolaemia as adults compared with formula‐fed infants.[10](#dom13240-bib-0010){ref-type="ref"}, [11](#dom13240-bib-0011){ref-type="ref"}, [12](#dom13240-bib-0012){ref-type="ref"}, [13](#dom13240-bib-0013){ref-type="ref"} Exposure to antibiotics in early life perturbs development of the gut microbiota, reduces *Bifidobacterium* abundance[14](#dom13240-bib-0014){ref-type="ref"} and predisposes infants to developing obesity later in life.[15](#dom13240-bib-0015){ref-type="ref"}, [16](#dom13240-bib-0016){ref-type="ref"} These studies unlock the potential of altering gut microbiota beneficially in early life to counteract the development of obesity and metabolic disease later in life.

Pre‐, pro‐ and synbiotics are known to affect gut microbiota composition beneficially.[17](#dom13240-bib-0017){ref-type="ref"}, [18](#dom13240-bib-0018){ref-type="ref"}, [19](#dom13240-bib-0019){ref-type="ref"}, [20](#dom13240-bib-0020){ref-type="ref"} For example, short‐chain galacto‐oligosaccharides (scGOS), long‐chain fructo‐oligosaccharides (lcFOS) as prebiotics or in combination with *Bifidobacterium breve M16 V* as a synbiotic increase bifidobacteria abundance in infants.[21](#dom13240-bib-0021){ref-type="ref"}, [22](#dom13240-bib-0022){ref-type="ref"}, [23](#dom13240-bib-0023){ref-type="ref"}, [24](#dom13240-bib-0024){ref-type="ref"} Furthermore, pre‐, pro‐ and synbiotics are indicated to improve the host\'s growth and metabolic health by microbiota‐induced mechanisms,[25](#dom13240-bib-0025){ref-type="ref"} but their long‐term effects on the host\'s metabolic health beyond intervention have not been well studied. Therefore, we tested whether nutritional intervention with these components early in life lessens the subsequent development of diet‐induced obesity and affects long‐term metabolic health in the host by supplementing with scGOS/lcFOS alone as a prebiotic or in combination with *Bifidobacterium breve M16 V* as a synbiotic in a well‐established nutritional programming rodent model.[26](#dom13240-bib-0026){ref-type="ref"}, [27](#dom13240-bib-0027){ref-type="ref"}

2. METHODS {#dom13240-sec-0006}
==========

All experimental procedures in this study were in accordance with the principles of good laboratory animal care and practice, and complied with national legislation, following the EU‐guidelines for the protection of animals used for scientific purposes, and were reviewed and approved by the Animal Experimental Committee DEC‐Consult in Bilthoven, The Netherlands (Study 1) and the Ethics Committee on Animal Care and Use in Gothenburg, Sweden (Study 2).

At 2 independent European locations, we investigated whether nutritional pre‐ and synbiotics protect mice against diet‐induced obesity in our nutritional programming model, as depicted in Figure [1](#dom13240-fig-0001){ref-type="fig"}A (Study 1) and Figure [S2](#dom13240-supitem-0005){ref-type="supplementary-material"}A (Study 2). On postnatal day (PN) 2, offspring from C57BL/6 J dams were randomly culled to 4 male and 2 female pups per litter, and lactating dams were assigned AIN‐93G‐based intervention diets supplemented with prebiotics (PRE: 2% w/w scGOS/lcFOS; Study 1 only), synbiotics (SYN: 2% w/w scGOS/lcFOS+10^9^ CFU/g *Bifidobacterium breve* M‐16 V \[Morinaga Milk Industries Ltd., Tokyo, Japan\]) or a non‐active control component (REF and CTRL: 2% w/w maltodextrin). In addition to dietary supplementation, pups received daily (PN10--15) an oral dose of approximately 10 to 15 mg/day maltodextrin or scGOS/lcFOS, with or without 1 × 10^9^ cfu *B. breve* M‐16V of their respective supplement. After weaning (PN21), male offspring were housed in pairs and continued respective intervention diets until PN42. Thereafter CTRL, PRE and SYN animals received a Western‐style diet (WSD, 40% energy from fat) as a challenge until sacrifice on PN98. A non‐supplemented, non‐WSD‐challenged group (REF) served as a normal healthy reference. Throughout the experiments, body weight and composition were determined, using either DEXA (Study 1) or MRI (Study 2), and faecal samples were collected on PN21, 42 and 98. On PN98, animal length was determined and blood plasma, white adipose tissue (WAT) depots, back‐hind muscles, liver and intestinal segments were collected, weighed, snap frozen and stored at −80 °C until further analysis.

![Early life synbiotics prevent excessive fat accumulation under WSD challenge. A, Schematic overview of Study1. Litters were culled at postnatal day (PN) 2 and were randomly divided into 4 diet groups: Reference (REF) and Control (CTRL) groups receiving AIN‐G (standard semi‐synthetic diet appropriate for breeding) plus control component (maltodextrin); the PRE group receiving AIN‐G supplemented with prebiotics (scGOS/lcFOS in ratio 9:1); and the SYN group receiving AIN‐G, supplemented with synbiotics (scGOS/lcFOS in a ratio 9:1 + B. breve M‐16V) until PN42. At PN42, the REF group was maintained on AIN‐M (semi‐synthetic diet appropriate for maintenance) and the CTRL, PRE and SYN groups were challenged with Western‐style diet (40% energy from fat) until PN98. Body weight (B), fat mass (C) and lean body mass (D) in the REF (n = 8), CTRL (n = 7), PRE (n = 9) and SYN (n = 11) groups of mice at PN42, PN70 and PN98. Sum of fat pads (E) and plasma leptin level (F) in the REF (n = 8), CTRL (n = 7), PRE (n = 9) and SYN (n = 11) groups of mice at PN98. Data are given as mean ± SEM. In (B) to (D), repeated‐measures two‐way ANOVA, followed by Sidak\'s multiple comparisons test for (1) REF vs CTRL (2), PRE vs SYN and (3) CTRL vs SYN. ^&&^ *P* ≤ .01, ^&&&^ *P* ≤ .001 indicates significance for REF vs CTRL. ^††^ *P* ≤ .01, ^†††^ *P* ≤ .001 indicate significance for PRE vs SYN. ^\$^ *P* ≤ .05, ^\$\$^ *P* ≤ .01; ^\$\$\$^ *P* ≤ .001 indicate significance for CTRL vs SYN. In (E) and (F), one‐way ANOVA, followed by Tukey\'s multiple comparisons test. \**P* ≤ .05](DOM-20-1408-g002){#dom13240-fig-0001}

Cecal contents of CTRL and SYN mice collected at PN42 in Study 2 were transplanted to age‐matched germ‐free C57BL/6 male recipients that were maintained on WSD for 8 weeks, and their body weight and composition were determined (Figure [5](#dom13240-fig-0005){ref-type="fig"}A).

Fasting total cholesterol, triglycerides, beta‐hydroxybutyrate, leptin, insulin and glucose were measured in plasma. Total triglyceride and cholesterol content were also measured in liver. RNA from duodenum, jejunum, ileum, colon, liver and WAT was extracted and hybridized to Affymetrix GeneChip Mouse Gene 1.1 ST microarrays. Gene expression was analysed using a Bioconductor software package‐based pipeline.[28](#dom13240-bib-0028){ref-type="ref"} Faecal microbiota composition was profiled by 16S rRNA gene sequencing using an Illumina MiSeq platform and data were analysed using the QIIME pipeline. Differentially abundant genera were identified based on negative binomial distribution (Wald test) using DESeq2 package in the R.

Detailed information related to study conduct, diets, sample collection and data analysis are available online in Appendix [S1](#dom13240-supitem-0001){ref-type="supplementary-material"}.

3. RESULTS {#dom13240-sec-0007}
==========

3.1. Early life synbiotics induce long‐term protection against diet‐induced obesity {#dom13240-sec-0008}
-----------------------------------------------------------------------------------

To explore whether modulating the gut microbiota in early life may have beneficial effects on metabolism in adulthood, we supplemented mouse diets with prebiotics (PRE; short chain galacto‐oligosaccharides \[scGOS\], long chain fructo‐oligosaccharides \[lcFOS\], ratio 9:1) or synbiotics (SYN; same as PRE plus *Bifidobacterium breve* M‐16V) (Study1) (Figure [1](#dom13240-fig-0001){ref-type="fig"}A) after birth until PN42. Subsequently, mice were fed a Western‐style diet (WSD) until PN98 and compared to mice that did not receive early life nutritional supplementation (CTRL). Early life nutritional supplementation did not affect developmental growth during the intervention period; no significant difference in body weight (*P* = .174), fat mass (*P* = .059), lean body mass (*P* = .097) (Figure [1](#dom13240-fig-0001){ref-type="fig"}B‐D) or adiposity (*P* = .324) (Figure [S1](#dom13240-supitem-0005){ref-type="supplementary-material"}) was observed between any of the groups at PN42. There were also no differences between groups in lean body mass development under WSD challenge (diet\*time interaction, *P* = .541) (Figure [1](#dom13240-fig-0001){ref-type="fig"}D) or in animal length at PN98 (*P* = .109) (Table [S1](#dom13240-supitem-0002){ref-type="supplementary-material"}), indicating a normal growth trajectory. The effectiveness of the WSD challenge was confirmed by accelerated weight gain (diet\*time interaction *P* \< .001) and increased fat disposition (diet\*time interaction *P* \< .001) in the CTRL group compared with non‐supplemented, non‐challenged healthy reference mice (REF) (Figure [1](#dom13240-fig-0001){ref-type="fig"}B,C).

We observed that early life synbiotics supplementation protected mice against diet‐induced obesity, as the SYN group had significantly reduced body weight and fat mass compared with the CTRL and PRE groups, both at PN70 (SYN vs CTRL, *P* ~BW~ = .012, *P* ~FM~ \< .001; SYN vs PRE, *P* ~BW~ = .007, *P* ~FM~ = .014) and PN98 (SYN vs CTRL, *P* ~BW~ = .004, *P* ~FM~ \< .001; SYN vs PRE, *P* ~BW~ = .002, *P* ~FM~ \< .001) (Figure [1](#dom13240-fig-0001){ref-type="fig"}B,C). In accordance with this observation, average fat mass percentage was reduced in the SYN group compared with the CTRL group at PN70 (*P* = .001) and PN98 (*P* = .002) (Figures [S1](#dom13240-supitem-0005){ref-type="supplementary-material"}B and [S1](#dom13240-supitem-0005){ref-type="supplementary-material"}C). Food intake did not differ between groups (data not shown).

Synbiotic supplementation also reduced individual fat pad weights (Table [S1](#dom13240-supitem-0002){ref-type="supplementary-material"}) and the sum of fat pad weights (*P* = .036) at PN98 in the SYN group compared with the CTRL group (Figure [1](#dom13240-fig-0001){ref-type="fig"}E). In agreement with reduced adiposity, we observed that plasma leptin was reduced in the SYN group compared with the CTRL group (Figure [1](#dom13240-fig-0001){ref-type="fig"}F). In contrast, body weight, fat mass, fat pad weights and leptin level did not differ significantly at any time point in the PRE group compared with the CTRL group, suggesting that PRE is more effective in combination with the probiotic component in protecting against diet‐induced obesity.

To test the robustness of the findings, the study was repeated in a second animal facility in another European country, and the results on body weight and adipose phenotype (Study 2) (Figure [S2](#dom13240-supitem-0005){ref-type="supplementary-material"}A) were reproduced. Synbiotic supplementation reduced both body weight (*P* = .031) and fat mass (*P* = .026) compared with the CTRL group at PN98 (Figures [S2](#dom13240-supitem-0005){ref-type="supplementary-material"}B and [S2](#dom13240-supitem-0005){ref-type="supplementary-material"}C). Lean body mass remained similar in the SYN and CTRL groups throughout the experiment (*P* ~PN70~ = .652, *P* ~PN98~ = .914), reflecting normal growth (Figure [S2](#dom13240-supitem-0005){ref-type="supplementary-material"}D). Thus, it seems that the beneficial long‐term effects of synbiotic supplementation in early life are independent of environmental conditions that may differ between animal facilities.

3.2. Early life synbiotics improve glucose and lipid metabolism in adulthood {#dom13240-sec-0009}
----------------------------------------------------------------------------

To address whether protection from obesity was also associated with improved metabolic parameters, we determined the HOMA‐IR index as a surrogate marker for insulin resistance and found that the SYN group showed a trend towards reduced HOMA‐IR (*P* = .067) compared with the CTRL group (Figure [2](#dom13240-fig-0002){ref-type="fig"}A), suggesting improved insulin sensitivity. This effect was driven mainly by reduced insulin levels (*P* = .039) in the SYN group compared with the CTRL group (Figure [2](#dom13240-fig-0002){ref-type="fig"}B), whereas fasting glucose levels were similar between groups (Figure [2](#dom13240-fig-0002){ref-type="fig"}C). While plasma levels of triglycerides (TG) were similar in all WSD‐challenged groups (*P* = .986) (Figure [2](#dom13240-fig-0002){ref-type="fig"}D), we observed that total plasma cholesterol was significantly reduced in the SYN group compared with the CTRL group (*P* = .003), resembling REF group levels (Figure [2](#dom13240-fig-0002){ref-type="fig"}E). In addition, we detected increased plasma levels of beta‐hydroxybutyrate (*P* = .047) in the SYN group compared with the CTRL group (Figure [2](#dom13240-fig-0002){ref-type="fig"}F), indicating higher fatty acid oxidation, which might contribute to protection against obesity and improved glucose metabolism.

![Early life synbiotics improve markers for glucose and lipid homeostasis in adult mice. HOMA‐IR (A) was calculated from fasted plasma insulin (B) and fasted plasma glucose levels (C) at PN98. Plasma triglycerides (D), total cholesterol (E) and beta‐hydroxybutyrate (F), liver weight (G) and hepatic triglycerides (H) at PN98 in the REF (n = 8), CTRL (n = 5‐7), PRE (n = 7‐9) and SYN (n = 10‐11) groups. Data are given as mean ± SEM. One‐way ANOVA, followed by Tukey\'s multiple comparisons test. \**P* ≤ .05; \*\**P* ≤ .01](DOM-20-1408-g004){#dom13240-fig-0002}

The improvement in adult plasma parameters following early life synbiotic supplementation was also associated with reduced liver weight (SYN vs CTRL, *P* = .017; SYN vs PRE, *P* = .016) and decreased hepatic TG content (SYN vs CTRL, *P* = .034; SYN vs PRE, *P* = .009) (Figure [2](#dom13240-fig-0002){ref-type="fig"}G and H). These data suggest that the protective effect of synbiotic supplementation against obesity is accompanied by improvements in metabolism, including parameters of glucose and lipid homeostasis.

3.3. Early life synbiotics alter cholesterol metabolism in the ileum in adulthood {#dom13240-sec-0010}
---------------------------------------------------------------------------------

To explore potential molecular mechanisms underlying the beneficial long‐term effects of early life synbiotic supplementation compared with the CTRL group, we performed microarray analysis of 6 relevant tissues harvested on PN98: duodenum, jejunum, ileum and colon, liver and white adipose tissue. We observed that 144 genes were differentially regulated (q ≤ .05) in ileum in the SYN vs CTRL comparison. Of these 144 genes, 57% were relatively less expressed in the SYN group compared with the CTRL group. In contrast, other tissues did not show differentially expressed genes after FDR adjustment in the SYN vs CTRL comparison, indicating that synbiotic supplementation in early life has the most pronounced effects on ileal gene expression in adulthood. Additional information on all differentially expressed genes and their functions in the ileum, as defined by the Gene Ontology (GO) Database, is provided online in Table [S2](#dom13240-supitem-0003){ref-type="supplementary-material"}.

To identify regulated biological functions and canonical pathways in the ileum for SYN vs CTRL comparison, we performed Ingenuity Pathway Analysis (IPA) on differentially expressed genes (q ≤ .05). "Lipid metabolism" was identified as one of the strongest regulated biological functions in the ileum of adult mice supplemented with synbiotics in early life compared with the CTRL group (Figure [3](#dom13240-fig-0003){ref-type="fig"}A). In agreement with this, the 4 most strongly regulated canonical pathways (Figure [3](#dom13240-fig-0003){ref-type="fig"}B) were: "LPS/IL‐1 mediated inhibition of RXR," related to the regulation of lipid, cholesterol and xenobiotic metabolism, "Superpathway of cholesterol biosynthesis," "Zymosterol Biosynthesis," feeding into cholesterol biosynthesis and "LXR/RXR activation," which is also related to lipid and cholesterol metabolism. This suggests that lipid and cholesterol metabolism are the most strongly regulated functions in adult mice following synbiotic supplementation in early life. Following this lead, we selected gene sets related to cholesterol metabolism and fate, including cholesterol biosynthesis, esterification, transport, distribution and regulation. The expression level of respective genes (n = 31), displayed as signal intensity per sample normalized to the mean signal of the CTRL group, is shown in the heatmap in Figure [3](#dom13240-fig-0003){ref-type="fig"}C, highlighting that the effects are strongest in SYN samples compared to the CTRL group. We observed that 6 of the selected 31 genes were significantly (q ≤ .05) regulated in SYN vs CTRL comparison, while other genes followed the same trend of regulation as indicated in the heatmap (Figure [3](#dom13240-fig-0003){ref-type="fig"}C). Gene sets related to cholesterol biosynthesis, that is, mevalonate pathway and steroid biosynthesis (*Hmgcs1*, *Pmvk*, *Tm7sf2*, *Msmo1* and *Nsdhl* with q ≤ 0.05) and cholesterol uptake into the cell were up‐regulated in adult mice with synbiotic supplementation in early life compared with the CTRL group (Figure [3](#dom13240-fig-0003){ref-type="fig"}C,D and Table [S3](#dom13240-supitem-0004){ref-type="supplementary-material"}). In contrast, genes related to cholesterol storage, distribution and excretion, including *Abca1* (q = 0.038), were down‐regulated in the SYN group vs the CTRL group (Figure [3](#dom13240-fig-0003){ref-type="fig"}C,D and Table [S3](#dom13240-supitem-0004){ref-type="supplementary-material"}). Taken together, synbiotic supplementation in early life induced the expression of genes involved in intestinal cholesterol synthesis and uptake in ileal cells of adult mice compared with CTRL mice receiving WSD. These observations for the SYN vs CTRL groups were largely in line with the effects in the REF vs CTRL groups (Figure [3](#dom13240-fig-0003){ref-type="fig"}C).

![Early life synbiotics affect cholesterol metabolism in the ileum on PN98. The 5 most strongly regulated regulated biological functions (A) and canonical pathways (B) in the SYN vs CTRL comparison in the ileum, determined by Ingenuity Pathway Analysis (IPA) of differential expressed genes (q ≤ .05). (C) Heatmap of selected gene sets related to cholesterol biosynthesis, esterification, transport, distribution and regulation, indicating relative gene expression (signal intensities per sample normalized to the mean of the CTRL group in the REF, CTRL, PRE and SYN groups as color gradient: red, higher expression than mean of CTRL; blue, lower expression than mean of CTRL). (D) Schematic overview of cholesterol biosynthesis pathway, transport, distribution and regulation. Up‐regulation (red) and down‐regulation (blue) are indicated for genes with *P* ≤ .05 in SYN vs CTRL comparison. Bold frames indicate significantly altered genes after FDR adjustment (q ≤ .05). White boxes indicate non‐significant genes (*P* \> .05). For more information see Table [S3](#dom13240-supitem-0004){ref-type="supplementary-material"}](DOM-20-1408-g003){#dom13240-fig-0003}

3.4. Early life synbiotics intervention induces subtle microbiota changes {#dom13240-sec-0011}
-------------------------------------------------------------------------

The microbiota composition of faecal samples collected at PN21, PN42 and PN98 was determined using Illumina MiSeq platform. In total, we generated 4 176 221 sequences with a mean ± SD of 42 184 ± 6391 sequences per sample. To investigate the variance within and between groups, weighted unifrac distances (sensitive to abundance of taxa) were obtained. We observed no significant difference in distances within the individual groups or between groups, or between distances within and between groups (Figure [4](#dom13240-fig-0004){ref-type="fig"}A). Alpha diversity, which reflects within sample diversity, measured by "observed species," was significantly higher in the SYN group compared with the PRE (*P* = .042) and CTRL (*P* = .006) groups at PN21 and PN42, respectively (Figure [4](#dom13240-fig-0004){ref-type="fig"}B), indicating that synbiotic supplementation increased early life faecal bacterial diversity.

![Early life synbiotics modulate early life microbiota. A, Weighted Unifrac distances showing distance within and between groups in the REF (n = 7), CTRL (n = 7), PRE (n = 8) and SYN (n = 11) groups of mice. B, Bacterial diversity as shown by diversity box plots obtained from alpha rarefaction measured by observed species. Data are shown as box and whiskers plots, indicating the median (thick line in the box), the 25th to 75th percentile range (boxes), and the 1st to 99th percentile range (whiskers). Relative abundance of major phyla (C), *Bifidobacterium* (D) *Lactobacillus* (E) and S24_7 (F) in the REF (n = 7), CTRL (n = 7), PRE (n = 8) and SYN (n = 11) groups of mice. Data are given as mean ± SEM. In (C), two‐way analysis of variance, followed by Tukey\'s multiple comparisons test. ^\$^ *P* \< .05, ^\$\$^ *P* \< .01, ^\$\$\$^ *P* \< .001 indicate significance between the CTRL and SYN groups. In (D) to (F), non‐parametric the Kruskal‐Wallis test, followed by Dunn\'s multiple comparisons test. \**P* \< .05, \*\**P* \< .01 as indicated](DOM-20-1408-g005){#dom13240-fig-0004}

To determine the overall microbiota structure over time, we analysed the microbiota composition at phylum level. The abundance of Firmicutes reduced in the SYN group compared with the CTRL and PRE groups at PN42 (Figure [4](#dom13240-fig-0004){ref-type="fig"}C). Synbiotic supplementation trended towards increasing the abundance of Actinobacteria at PN42 and reached statistical significance at PN98 compared with the CTRL group (Figure [4](#dom13240-fig-0004){ref-type="fig"}C). At PN98, the abundance of Bacteroidetes was significantly reduced in the SYN group compared with the CTRL group, while the level of Firmicutes did not differ between these groups (Figure [4](#dom13240-fig-0004){ref-type="fig"}C). Levels of abundant genera that differed across different time points were plotted in Figure [4](#dom13240-fig-0004){ref-type="fig"}D‐F to explain observed phenotypic differences between the groups. The abundance of *Bifidobacterium* was highest in the synbiotic‐supplemented group compared with the CTRL group at PN21 (Figure [4](#dom13240-fig-0004){ref-type="fig"}D). Moreover, a higher proportion of *Bifidobacterium* in the SYN group, compared with all other groups including the PRE group, was maintained until PN98 (Figure [4](#dom13240-fig-0004){ref-type="fig"}D). The level of *Lactobacillus* fluctuated at different time points and was not significantly altered in the SYN group compared with the CTRL group at any time point (Figure [4](#dom13240-fig-0004){ref-type="fig"}E). The relative abundance of unidentified genus from family S24_7, belonging to phylum Bacteroidetes, increased in the SYN group compared with the CTRL group at PN42, but decreased at PN98 (Figure [4](#dom13240-fig-0004){ref-type="fig"}F). We also identified differentially abundant genera that were altered in the SYN vs CTRL comparison at different time points, using negative binomial generalized linear models (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}). Interestingly, a low‐abundance unidentified genus from Alphaproteobacteria (order RF32) was identified as the most differentially abundant genus, with higher levels in the SYN group compared with the CTRL group at all 3 time points (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}A). At PN42, *Lactobacillus* was identified with logFC = −1.40 (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}A), consistent with its trend of lower abundance in the SYN group compared with the CTRL group (Figure [4](#dom13240-fig-0004){ref-type="fig"}E). In addition, *Dorea* (logFC = 4.31) and *Parabacteroides* (logFC = −1.67) were also identified at PN42 (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}A).

Next, we performed sequencing of the samples obtained in the second facility (Study 2) at PN21, PN42 and PN98 (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}), using the same protocol. Weighted unifrac distances revealed that distance within the SYN group was significantly reduced from that in the CTRL vs SYN and SYN vs REF comparison at PN21, and the SYN vs REF comparison at PN98 (Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}A), indicating altered bacterial composition. Alpha diversity did not differ between groups (Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}B). At phylum level, there was a reduction in abundance of Bacteroidetes with no difference in levels of Firmicutes in SYN mice compared with CTRL mice at PN98 (Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}C). The relative abundance of *Bifidobacterium* was higher in the SYN group vs the CTRL group at PN21 (similar to Figure [4](#dom13240-fig-0004){ref-type="fig"}D), but it was not maintained at PN42 and PN98 (Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}D). The level of *Lactobacillus* was reduced in the SYN group compared with the CTRL group at PN21 (Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}E). The relative abundance of unidentified genus from family S24_7 increased following SYN supplementation at PN21, but was not maintained at later time points (Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}F). DESeq2 analysis revealed *Bifidobacterium* (log FC = 1.35) and an unidentified genus from family S24_7 (logFC = 1.30) that showed higher levels in the SYN group compared with the CTRL group at PN21 (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}B), consistent with data presented in Figure [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}D and [S4](#dom13240-supitem-0005){ref-type="supplementary-material"}F. Interestingly, we also identified the low‐abundance genus *Akkermansia* that showed lower levels at PN21 (logFC = −2.34) and then increased (logFC = 6.58) at PN98 in the SYN group vs the CTRL group, probably coinciding with shifts in diet (Figure [S3](#dom13240-supitem-0005){ref-type="supplementary-material"}B). Thus, we observed different taxonomic changes within the microbiota, despite similar metabolic outcomes of nutritional intervention.

3.5. Microbiota transplant in adolescence does not transfer beneficial phenotype of synbiotics {#dom13240-sec-0012}
----------------------------------------------------------------------------------------------

To determine whether the improved adult metabolic phenotype of SYN mice was mediated by altered microbiota, we colonized 6‐week‐old germ‐free (GF) mice with cecal content from age‐matched CTRL or SYN donor mice and determined the development of body weight and body composition under WSD challenge over 8 weeks (Figure [5](#dom13240-fig-0005){ref-type="fig"}A). At the time of transfer (PN42), there were no differences in body weight, fat mass and lean body mass (*P* = .996; *P* \> .999; *P* = .604, respectively) between recipient GF mice (Figure [5](#dom13240-fig-0005){ref-type="fig"}B‐D). Following microbiota transfer, we observed no significant differences in development of body weight (*P* = .310), fat mass (*P* = .902) or lean body mass (*P* = 0.302) between the CTRL and SYN groups (Figure [5](#dom13240-fig-0005){ref-type="fig"}B‐D). Thus, transferring the modified microbiota after synbiotic supplementation to age‐matched adolescent recipients is not sufficient to transfer the protected phenotype of synbiotic‐supplemented mice.

![Beneficial phenotype induced by synbiotics is not transferred by microbiota transplant in early adulthood. A, Schematic overview of Study. Six‐weeks‐old germ‐free (GF) mice maintained on standard diet were transplanted with cecal contents collected from CTRL or SYN mice at PN42. Both transplanted groups (ie,. tCTRL and tSYN) were challenged by Western‐style diet until PN98. Body weight (B), fat mass (C) and lean body mass (D) in tCTRL (n = 8) and tSYN (n = 9) groups of mice at PN42, PN70 and PN98. Data are given as mean ± SEM. Repeated‐measures two‐way ANOVA, followed by Sidak\'s multiple comparisons test](DOM-20-1408-g001){#dom13240-fig-0005}

4. DISCUSSION {#dom13240-sec-0013}
=============

Perturbation of the gut microbiota in early life by antibiotics has been shown to promote development of obesity and an adverse metabolic phenotype later in life.[15](#dom13240-bib-0015){ref-type="ref"}, [16](#dom13240-bib-0016){ref-type="ref"}, [29](#dom13240-bib-0029){ref-type="ref"} In the present study, we showed that beneficial modulation of the gut microbiota by early life synbiotics, consisting of scGOS/lcFOS plus *Bifidobacterium breve M16V*, but not by the prebiotic component alone, protected against later‐life development of diet‐induced obesity, reproducibly in 2 different locations. Early life synbiotics also improved the adult metabolic phenotype and induced long‐term changes in gene expression patterns, specifically in the ileum, related to lipid and cholesterol metabolism in adult mice. Although we observed similar metabolic improvements in the 2 vivaria following synbiotic supplementation, the taxonomic configuration of the microbiota differed, apart from the similarly increased *Bifidobacterium* abundance in early life. Furthermore, cecal microbiota transplantation from adolescent donors did not transfer the protective phenotype against diet‐induced obesity in age‐matched GF recipients, indicating a critical window of opportunity for the effectiveness of microbiota modulation. Thus, early synbiotic supplementation improves metabolic health later in life and affects the gut microbiota.

We did not detect any direct effects of prebiotics or synbiotics on developmental growth and body composition during the intervention period itself. This is in accordance with previous clinical intervention studies that showed that applied prebiotics and synbiotic blend support normal growth in healthy full‐term infants.[30](#dom13240-bib-0030){ref-type="ref"}, [31](#dom13240-bib-0031){ref-type="ref"}, [32](#dom13240-bib-0032){ref-type="ref"}, [33](#dom13240-bib-0033){ref-type="ref"}, [34](#dom13240-bib-0034){ref-type="ref"}, [35](#dom13240-bib-0035){ref-type="ref"} Under moderate WSD challenge following the intervention, we found that the SYN group was protected against diet‐induced excessive fat accumulation and related accelerated weight gain compared with the CTRL group. In contrast, the prebiotic group did not show protection against diet‐induced obesity. As we did not investigate the effects of *B. breve* M‐16V alone, we cannot exclude that the beneficial effects observed in the SYN group are mainly mediated by the bacterium. Apart from the knowledge that human milk, containing naturally occurring pre‐ and probiotics, is protective against metabolic disturbances later in life,,[11](#dom13240-bib-0011){ref-type="ref"}, [12](#dom13240-bib-0012){ref-type="ref"}, [25](#dom13240-bib-0025){ref-type="ref"}, [36](#dom13240-bib-0036){ref-type="ref"}, [37](#dom13240-bib-0037){ref-type="ref"} there is only 1 study with a prevention paradigm, showing that early probiotic supplementation in pregnant mothers and infants for 6 months supports healthy growth in infants up to 4 years of age,[38](#dom13240-bib-0038){ref-type="ref"} which is consistent with our findings. Another probiotic intervention in infants during weaning (at 4‐13 months of age) resulted in no beneficial effect on growth and metabolic parameters,[39](#dom13240-bib-0039){ref-type="ref"} indicating the importance of the timing for effectiveness of dietary supplements. In a treatment setting, however, there is substantial evidence that pre‐ and synbiotics can improve metabolic disorders and support weight loss.[40](#dom13240-bib-0040){ref-type="ref"}, [41](#dom13240-bib-0041){ref-type="ref"}

The protection against adult obesity via early life synbiotics was associated with improved glucose metabolism, decreased hepatic lipid deposition and attenuated hypercholesterolaemia in adulthood. The reduced steatosis was associated with increased serum levels of beta‐hydroxybutyrate, suggesting that SYN intervention, in part, acts by increasing fatty acid oxidation. It is known that pro‐ and synbiotics are successful for treatment of fatty liver disease,[40](#dom13240-bib-0040){ref-type="ref"}, [42](#dom13240-bib-0042){ref-type="ref"}, [43](#dom13240-bib-0043){ref-type="ref"} with intestinal microbiota being indicated in the mode of action.[44](#dom13240-bib-0044){ref-type="ref"}, [45](#dom13240-bib-0045){ref-type="ref"}

Our transcriptomic analyses for exploration of molecular long‐term changes induced by early life synbiotic supplementation revealed the strongest effects on gene expression related to lipid metabolism in the small intestine in adult mice, which is a major contributor to the cholesterol pool.[46](#dom13240-bib-0046){ref-type="ref"}, [47](#dom13240-bib-0047){ref-type="ref"} In synbiotic‐supplemented mice compared with CTRL mice, we detected a collective activation of genes related to cholesterol biosynthesis upon WSD challenge in the ileum, while the expression of genes related to cholesterol excretion, such as *Abca1* was down‐regulated. In type 2 diabetic rats, *Abca1* is increased in intestinal epithelial cells.[48](#dom13240-bib-0048){ref-type="ref"} Thus, down‐regulation of intestinal *Abca1,* plus higher intestinal cholesterol synthesis in SYN‐supplemented mice, concurrent with beneficially decreased blood cholesterol levels, might be an adaptive mechanism to cope with the higher cholesterol requirement in ileal enterocytes.

Pre‐, pro‐ and synbiotic supplementation is associated with beneficial changes in the gut microbiome in mice[49](#dom13240-bib-0049){ref-type="ref"} and humans.[22](#dom13240-bib-0022){ref-type="ref"}, [23](#dom13240-bib-0023){ref-type="ref"}, [50](#dom13240-bib-0050){ref-type="ref"}, [51](#dom13240-bib-0051){ref-type="ref"} We observed that early life synbiotics altered the microbiome, with a significant increase in genus *Bifidobacterium* at PN21 in both independent experiments. This is in line with previous studies advocating addition of pre‐ and synbiotic supplements to infant formula.[21](#dom13240-bib-0021){ref-type="ref"}, [22](#dom13240-bib-0022){ref-type="ref"}, [23](#dom13240-bib-0023){ref-type="ref"}, [24](#dom13240-bib-0024){ref-type="ref"} The bifidogenic effect of our early life synbiotic supplementation may drive the observed anti‐obesity effects, as childhood obesity has been linked to depletion of the early life bifidobacteria abundance.[52](#dom13240-bib-0052){ref-type="ref"}, [53](#dom13240-bib-0053){ref-type="ref"} For the prebiotic component alone, whose effect depends on already‐present resident microbes at the time of intervention,[17](#dom13240-bib-0017){ref-type="ref"} we did not observe a bifidogenic effect. It is interesting to note that other taxonomic changes were not similar in the 2 independent locations, but metabolic phenotypes were reproducible. Furthermore, we showed with our transplant experiment that transferring the synbiotics‐modified microbial community from adolescent donors (at PN42) to age‐matched GF mice does not confer protection against diet‐induced obesity in recipients. This implicates the importance of the timing of microbiota modulation; that is, exposure to synbiotics in early life is relevant for achieving long‐lasting beneficial and protective metabolic effects. Provided that the gut microbiota differed between P21 and P42, we cannot exclude that the microbiota transplant from PN21 donors might have produced a different result. Nevertheless, our data strengthen the notion of the importance of breastfeeding and synbiotic supplementation of infant formulas in early life to promote the bifidogenic effect in infants, thereby improving metabolism and protecting against metabolic disorders later in life.

In conclusion, this study adds evidence that early colonization of the digestive tract by symbiotic microbes may be critical for healthy metabolic development, and maintenance of a healthy metabolism in adulthood. With nutritional interventions in a relevant rodent model, we show that early life synbiotic supplementation can protect against the development of obesity and metabolic disease later in life. Obesity in adults and children is on the rise globally and there is no powerful cure, other than bariatric surgery, for this worldwide epidemic and its associated metabolic impairments. Our study provides important insights into the beneficial effects of supplementation with synbiotics in early life, which may lead to the development of preventive strategies; however, validation in humans is warranted.

Supporting information
======================

###### 

**Appendix S1**. Material & Methods.

###### 

Click here for additional data file.

###### 
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**Table S2.** List of all differentially expressed genes (q \< 0.05) in ileum of SYN compared with CTRL on PN98 and annotation. Data is based on microarrays of ileal tissue on PN98 in CTRL and SYN mice; n = 4 per group; Intensity‐based moderate t‐statistics (IBMT) with empirical Bayes correction of SYN vs. CTRL; annotated with Gene Ontology (GO) database.
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**Table S3.** Gene expression fold changes, p‐values and q‐values of genes related to cholesterol metabolism in ileum of REF, CTRL, PRE and SYN groups on PN98. Data is based on microarrays of ileal tissue on PN98 in REF, CTRL, PRE and SYN groups; n = 4 per group; Intensity‐based moderate t‐statistics (IBMT) with empirical Bayes correction of (i) SYN vs. CTRL; (ii) PRE vs. CTRL and (iii) CTRL‐REF.

###### 

Click here for additional data file.

###### 

**Figure S1.** Early life synbiotics reduce fat mass percentage.

Fat mass (expressed as fat mass %) at PN42 (A), PN70 (B) and PN98 (C) in REF (n=8), CTRL (n=7), PRE (n=9) and SYN (n=11) groups of mice. Data are mean ± SEM. One‐way ANOVA followed by Tukey\'s multiple comparisons test. \*p≤0.05; \*\*\*p≤0.001.

**Figure S2.** Prevention of excessive fat accumulation by early life synbiotics under WSD challenge is reproducible.

\(A\) Schematic overview of Study2. Litters were culled at postnatal day (PN) 2 and were divided into 3 diet groups: Reference (REF) and Control (CTRL) on AIN‐G (standard semi‐synthetic diet appropriate for breeding) plus control component (maltodextrin), and SYN on AIN‐G supplemented with synbiotics (scGOS/lcFOS in ratio 9:1 + *B.breve* M‐16V) until PN42. At PN42, REF was maintained on AIN‐M (semi‐synthetic diet appropriate for maintenance) and CTRL and SYN groups were challenged with Western‐style diet (40% energy from fat) until PN98.

Body weight (B), fat mass (C) and lean body mass (D) in REF (n=6), CTRL (n=9) and SYN (n=8) groups of mice at PN42, PN70 and PN98. Data are mean ± SEM. Repeated‐measures two‐way ANOVA followed by Sidak\'s multiple comparisons test for (i) REF vs. CTRL and (ii) CTRL vs. SYN. ^&&&^p≤0.001 indicates significance for REF vs. CTRL. ^\$^p≤0.05 indicates significance for CTRL vs. SYN.

**Figure S3.** Differentially abundant genera identified using negative binomial distribution method (DESEq2).

Differentially abundant genera identified in CTRL versus SYN comparison at PN21, PN42 and PN98 in study 1 and study 2. LogFC indicates the log fold change in the SYN versus CTRL comparison; negative values indicate lower while positive values indicate higher abundance in synbiotic (SYN) compared with WSD fed group (CTRL). All genera identified are significant at padj≤0.05. The genera names are italicized; unidentified genera are indicated as 'g' with their known closest rank.

**Figure S4.** Early life microbiota modulation by early life synbiotics in study 2.

Weighted Unifrac distances showing distance within and between groups in REF (n=7), CTRL (n=12) and SYN (n=11) groups of mice. Significance between the groups was analyzed by default 2 sample t‐test in Qiime, \*p\<0.05. (B) Bacterial diversity as shown by diversity box plots obtained from alpha rarefaction measured by observed species. Data are shown as box and whiskers plots, indicating the median (thick line in the box), the 25‐75th percentile range (boxes), and the 1‐99th percentile range (whiskers). Relative abundance of (C) major phyla (D) *Bifidobacterium* (E) *Lactobacillus* and (F) S24_7 in REF (n=7), CTRL (n=12) and SYN (n=11) groups of mice. Data are mean ± SEM. In C, two‐way analysis of variance followed by Tuckey\'s multiple comparisons test. ^\$^p≤0.05, ^\$\$\$^p≤0.001 indicates significance between CTRL and SYN. In D‐F, non‐parametric Kruskal‐Wallis test followed by Dunn\'s multiple comparisons test. \*\*p≤0.01; \*\*\*p≤0.001 as indicated.
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